DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Surmontil (Trimipramine Maleate) - Summary

 
 



BOX WARNING

Suicidality and Antidepressant Drugs

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Surmontil or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Surmontil is not approved for use in pediatric patients. (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use)

 

SURMONTIL SUMMARY

Surmontil is an antidepressant with an anxiety-reducing sedative component to its action.

Surmontil is indicated for the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. In studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. In hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression.


See all Surmontil indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Surmontil (Trimipramine)

Activating neurons that trigger depression could help treat it, study suggests
Source: Anxiety / Stress News From Medical News Today [2014.04.19]
Researchers from the Icahn School of Medicine at Mount Sinai found that activating neurons linked to stress-induced depression may actually increase resilience to the condition.

Stroke Rounds: Depression Tied to Worse Stroke Outcomes (CME/CE)
Source: MedPage Today Cardiovascular [2014.04.17]
(MedPage Today) -- Depression was found to be a significant and independent risk factor for poor stroke outcomes in a study from the U.K., and recovery from depression within a year did not alter long-term risk.

Symptoms of depression surge in young men during early fatherhood
Source: Depression News From Medical News Today [2014.04.16]
Depression can hit young fathers hard -- with symptoms increasing dramatically during some of the most important years of their children's lives, a new Northwestern MedicineR study has found.

Study: When depression does not respond to treatment
Source: Complementary Medicine / Alternative Medicine News From Medical News Today [2014.04.15]
Notwithstanding numerous advances in the pharmacological treatment of depression, approximately 70% of patients do not remit after first-line antidepressant treatment.

Preschool Depression Strong Predictor of Later MDD
Source: Medscape Psychiatry & Mental Health Headlines [2014.04.14]
Preschoolers with depressive syndrome run a significantly increased risk for major depression later in childhood.
Medscape Medical News

more news >>

Published Studies Related to Surmontil (Trimipramine)

Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial. [2009.04]
BACKGROUND: Patients with delusional depression are difficult to treat. The atypical antidepressant trimipramine was effective in a previous 4-week open label pilot study in patients with this disorder. The major neurobiological effect of trimipramine is the inhibition of the hypothalamic-pituitary-adrenocortical (HPA) system. In delusional depression HPA overactivity is more distinct than in other subtypes of depression. HPA suppression is thought to contribute to the action of trimipramine... CONCLUSION: In all, trimipramine monotherapy appears to be an effective treatment in delusional depression.

Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol - A double-blind multicenter trial. [2008.11.25]
BACKGROUND: Patients with delusional depression are difficult to treat. The atypical antidepressant trimipramine was effective in a previous 4-week open label pilot study in patients with this disorder. The major neurobiological effect of trimipramine is the inhibition of the hypothalamic-pituitary-adrenocortical (HPA) system. In delusional depression HPA overactivity is more distinct than in other subtypes of depression. HPA suppression is thought to contribute to the action of trimipramine... CONCLUSION: In all, trimipramine monotherapy appears to be an effective treatment in delusional depression.

Fluoxetine versus trimipramine in the treatment of depression in geriatric patients. [2005.01]
CONCLUSION: These findings suggest that fluoxetine and trimipramine are comparable in terms of efficacy and tolerability in the treatment of major depression in geriatric patients.

Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine. [2003.03]
CONCLUSION: Trimipramine failed to exhibit therapeutic equivalence to perazine in the dosages used. However, there was evidence of a substantial antipsychotic effect of trimipramine. It may be a useful medication if depressive symptoms in psychotic patients require antidepressant treatment or if other antipsychotics cannot be administered.

Differential effects of trimipramine and fluoxetine on sleep in geriatric depression. [2001.03]
The effects of trimipramine, a tricyclic antidepressant (TCA) with atypical pharmacological properties, and fluoxetine, a selective serotonine reuptake inhibitor (SSRI), were compared in an exploratory analysis using mood and polysomnographic parameters during a six-week double-blind trial in 19 depressed geriatric patients.

more studies >>

Clinical Trials Related to Surmontil (Trimipramine)

Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Recruiting]
Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans associated with multiple episodes of depression and may also reverse the reduction of volume caused by the depression. In addition, genetic markers for serotonin are implicated with depression, and may be an indication of reduced response to antidepressant treatments.

This study aims to enroll patients who are defined as having treatment resistant depression (no remission after at least 2 treatments trials with an antidepressant). They will receive an MRI scan at the initial visit and either 6 months after sustained remission or 12 months after they enter the study for non-remitters. They will also be asked to give a blood sample for genotyping. They will be matched by age and handedness to healthy volunteers with no personal history of depression who will also receive an MRI scan and genotyping.

The first aim is to compare hippocampal volume of depressed subjects to healthy controls. It is anticipated that subjects will initially have smaller hippocampal volume but of those who sustain remission, there will be a small increase in hippocampal volume. It is also anticipated that specific genetic markers will be related to individuals response to antidepressant treatments.

more trials >>

Reports of Suspected Surmontil (Trimipramine) Side Effects

Rhabdomyolysis (4)Renal Failure Acute (4)Delirium (4)Confusional State (3)Therapeutic Response Increased (3)Disorientation (3)Medication Error (3)Hyponatraemia (3)Tremor (3)Drug Interaction (2)more >>


Page last updated: 2014-04-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012